Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

New approved medication for Premature Ejaculation

PRILIGY®. New approved medication for Premature Ejaculation available for New Zealand men

Janssen-Cilag announced that PRILIGY® (dapoxetine) is now approved and available for use in New Zealand for the treatment of premature ejaculation (PE) in men 18-64 years of age.

PE is a common men’s medical condition, but it is rarely talked about. However, it is widespread and could affect the quality of life of an estimated 250,000 New Zealand men and their partners[1].

Dr. Warrick White, an Auckland GP who specialises in men’s sexual health explains, “Despite up to 20-24% of men over 24 years of age experiencing PE at some point in their lives[2], the social stigma attached to the condition may cause men to be embarrassed and reluctant to talk to a doctor about ways to improve their condition”.

PE can be a distressing condition that can be present from the first sexual encounter or can develop later in life for a variety of reasons. Nearly 1 out of 4 men with PE (24.4%) reports significant levels of anxiety[3].

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

The symptoms of PE are: a short time to ejaculation, not being able to control when ejaculation happens and distress relating to either of these situations.
PRILIGY® is a medicine specifically developed for the treatment of PE. It is an oral tablet that can be taken approximately 1-3 hours before sex is anticipated. PRILIGY® is an unfunded medicine (men will need to pay for it) and available only with a prescription.

For further information on PRILIGY® visit www.priligy.co.nz

ENDS

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.